These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 17178794)

  • 61. Isoniazid and its toxic metabolite hydrazine induce in vitro pyrazinamide toxicity.
    Tostmann A; Boeree MJ; Peters WH; Roelofs HM; Aarnoutse RE; van der Ven AJ; Dekhuijzen PN
    Int J Antimicrob Agents; 2008 Jun; 31(6):577-80. PubMed ID: 18358703
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Fixed-dose combination chemotherapy (Rifater/Rifinah) for active pulmonary tuberculosis in Taiwan: a two-year follow-up.
    Su WJ; Perng RP
    Int J Tuberc Lung Dis; 2002 Nov; 6(11):1029-32. PubMed ID: 12475151
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Preventive therapy of tuberculosis with rifapentine in immunocompetent and nude mice.
    Chapuis L; Ji B; Truffot-Pernot C; O'Brien RJ; Raviglione MC; Grosset JH
    Am J Respir Crit Care Med; 1994 Nov; 150(5 Pt 1):1355-62. PubMed ID: 7952564
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Population pharmacokinetics, optimised design and sample size determination for rifampicin, isoniazid, ethambutol and pyrazinamide in the mouse.
    Chen C; Ortega F; Alameda L; Ferrer S; Simonsson US
    Eur J Pharm Sci; 2016 Oct; 93():319-33. PubMed ID: 27473307
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Radiosynthesis and bioimaging of the tuberculosis chemotherapeutics isoniazid, rifampicin and pyrazinamide in baboons.
    Liu L; Xu Y; Shea C; Fowler JS; Hooker JM; Tonge PJ
    J Med Chem; 2010 Apr; 53(7):2882-91. PubMed ID: 20205479
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Treatment of tuberculosis in HIV infection.
    Grosset JH
    Tuber Lung Dis; 1992 Dec; 73(6):378-83. PubMed ID: 1337993
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Altered drug exposures of first-line TB drugs in a moxifloxacin-containing treatment regimen.
    Perumal R; Arodola-Oladoyinbo O; Naidoo A; Kawuma AN; Naidoo K; Gengiah TN; Chirehwa M; Padayatchi N; Denti P
    Int J Tuberc Lung Dis; 2022 Aug; 26(8):766-774. PubMed ID: 35898135
    [No Abstract]   [Full Text] [Related]  

  • 68. Pyrazinamide: the importance of uncovering the mechanisms of action in mycobacteria.
    Stehr M; Elamin AA; Singh M
    Expert Rev Anti Infect Ther; 2015 May; 13(5):593-603. PubMed ID: 25746054
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Selective Inactivity of Pyrazinamide against Tuberculosis in C3HeB/FeJ Mice Is Best Explained by Neutral pH of Caseum.
    Lanoix JP; Ioerger T; Ormond A; Kaya F; Sacchettini J; Dartois V; Nuermberger E
    Antimicrob Agents Chemother; 2016 Feb; 60(2):735-43. PubMed ID: 26574016
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Evaluation of moxifloxacin-containing regimens in pathologically distinct murine tuberculosis models.
    Li SY; Irwin SM; Converse PJ; Mdluli KE; Lenaerts AJ; Nuermberger EL
    Antimicrob Agents Chemother; 2015 Jul; 59(7):4026-30. PubMed ID: 25918146
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Efficacy of intermittent pyrazinamide in experimental murine tuberculosis.
    Dickinson JM; Mitchison DA
    Tubercle; 1991 Jun; 72(2):110-4. PubMed ID: 1949213
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Spectinamides are effective partner agents for the treatment of tuberculosis in multiple mouse infection models.
    Robertson GT; Scherman MS; Bruhn DF; Liu J; Hastings C; McNeil MR; Butler MM; Bowlin TL; Lee RB; Lee RE; Lenaerts AJ
    J Antimicrob Chemother; 2017 Mar; 72(3):770-777. PubMed ID: 27999020
    [TBL] [Abstract][Full Text] [Related]  

  • 73. In vitro Synergism of Six Antituberculosis Agents Against Drug-Resistant
    Ying R; Huang X; Gao Y; Wang J; Liu Y; Sha W; Yang H
    Infect Drug Resist; 2021; 14():3729-3736. PubMed ID: 34548797
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Cost Resulting from Anti-Tuberculosis Drug Shortages in the United States: A Hypothetical Cohort Study.
    Scott JC; Shah N; Porco T; Flood J
    PLoS One; 2015; 10(8):e0134597. PubMed ID: 26284924
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Formulation of Tyloxapol niosomes for encapsulation, stabilization and dissolution of anti-tubercular drugs.
    Mehta SK; Jindal N
    Colloids Surf B Biointerfaces; 2013 Jan; 101():434-41. PubMed ID: 23010052
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Activities of TMC207, rifampin, and pyrazinamide against Mycobacterium tuberculosis infection in guinea pigs.
    Shang S; Shanley CA; Caraway ML; Orme EA; Henao-Tamayo M; Hascall-Dove L; Ackart D; Lenaerts AJ; Basaraba RJ; Orme IM; Ordway DJ
    Antimicrob Agents Chemother; 2011 Jan; 55(1):124-31. PubMed ID: 20937788
    [TBL] [Abstract][Full Text] [Related]  

  • 77. [Absorption and urinary elimination of pyrazinamid administered alone or in combination with isoniazid and rifampicin].
    Boulahbal F; Khaled S; Bouhassen H; Larbaoui D
    Arch Inst Pasteur Alger; 1978-1979; 53():165-85. PubMed ID: 262962
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Nanoparticle encapsulated antitubercular drugs as a potential oral drug delivery system against murine tuberculosis.
    Pandey R; Zahoor A; Sharma S; Khuller GK
    Tuberculosis (Edinb); 2003; 83(6):373-8. PubMed ID: 14623168
    [TBL] [Abstract][Full Text] [Related]  

  • 79.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 80.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.